real peptides FAQ

Follistatin-344's effect diminishes proportionally. Individuals with loss-of-function myostatin mutations (e.g., the MSTN K153R polymorphism found in Belgian Blue cattle and rare human cases) exhibit baseline muscle mass 20–40% above population norms. Adding exogenous follistatin produces marginal additional benefit because the inhibitory pathway is already compromised. The compound works by removing a brake; if the brake is already released, further follistatin provides little additional derepression.

Discard it if ambient temperature exceeded 25°C for more than 4 hours. Peptide bond hydrolysis accelerates exponentially above refrigeration temperature. At 30°C (common indoor summer temperature), KPV loses approximately 8–12% potency per 24-hour period. Visual inspection can't detect partial degradation. A vial that looks clear and colourless may have lost 30–40% activity after overnight temperature excursion. Using degraded peptide isn't dangerous, but it delivers subtherapeutic doses that waste protocol time and create misleading "non-responder" conclusions.

Request the full analytical report including the HPLC chromatogram and mass spectrum. The purity percentage is meaningless without the raw data showing how it was calculated. A legitimate supplier provides this documentation immediately; evasive responses indicate the claimed purity may be extrapolated from outdated testing or industry averages rather than actual batch analysis. Without chromatogram peaks showing retention time alignment and mass spectrum confirmation at 4963.5 Da, you're trusting unverifiable claims.

Shift administration earlier (5–6am) or reduce the dose. Tesofensine's norepinephrine elevation persists 12–16 hours post-dose due to the compound's long half-life. Individuals with slower hepatic metabolism (CYP2D6 poor metabolisers) may experience prolonged sympathetic activation extending into evening hours. If sleep disruption continues at the lowest effective dose, tesofensine may not be appropriate for that individual. Chronic sleep restriction reduces insulin sensitivity and increases cortisol, negating thermogenic metabolic benefits.

Verify administration route and injection technique first. Intranasal delivery or incorrect reconstitution ratios are the most common causes of subtherapeutic dosing. P21's effects are cumulative and structural, not acute and stimulant-like. If you're expecting racetam-style clarity boosts within hours, you're measuring the wrong endpoint. Assess after 4 weeks using objective metrics: memory recall tests, timed problem-solving tasks, or language retention drills. Subjective "I feel sharper" reports lag behind measurable performance gains by 10–14 days in most protocols.

Cloudiness indicates either bacterial contamination (if bacteriostatic water wasn't used or the vial seal was compromised) or peptide aggregation (if the solution experienced a temperature excursion or pH shift). Do not inject cloudy solutions. Aggregated peptides can trigger immune responses, and contaminated solutions carry infection risk. This failure pattern suggests either improper initial reconstitution or a storage error. Review your technique before reconstituting the next vial.

Contact the supplier for a replacement before reconstituting. IGF-1 LR3 is hygroscopic. It absorbs atmospheric moisture that begins degrading peptide bonds within hours of exposure. A vial without vacuum seal or desiccant has been exposed to ambient humidity during shipping, which reduces peptide potency even if the lyophilized cake appears intact. Moisture-exposed peptides may reconstitute normally but deliver inconsistent results due to partial degradation. Reputable suppliers replace compromised shipments without question. If the supplier resists replacement, it signals inadequate quality control and unreliable sourcing practices.

Discard the vial immediately. Dark green indicates oxidation of the copper ion from Cu²⁺ to Cu³⁺, which no longer coordinates with the peptide. This oxidation occurs when the solution is exposed to air for extended periods (more than 2 minutes during reconstitution) or stored without refrigeration. The pale blue colour is the signature of the intact AHK-Cu complex absorbing at 620nm. Loss of this colour means loss of the coordination bond. Do not attempt to use discoloured solution, even if it was prepared correctly. Oxidised copper generates reactive oxygen species that damage keratinocytes rather than stimulate follicles.

Discard the vial immediately. Cloudiness or visible particles indicate protein aggregation caused by improper reconstitution technique (shaking instead of swirling), contaminated bacteriostatic water, or temperature damage during shipping. Aggregated proteins lose receptor-binding activity and can trigger immune responses. IGF-1 LR3 should appear as a clear, colorless solution after reconstitution. Any deviation from this appearance means the peptide is no longer viable. Our quality assurance protocols ensure every batch ships with temperature monitoring, but reconstitution errors are user-side variables we can't control remotely.

Reduce dose to 0.5mg per application and confirm you're not using daily frequency. Irritation typically signals copper ion accumulation exceeding local antioxidant capacity. The solution is lower cumulative weekly copper load, not higher peptide purity. If irritation persists at 0.5mg applied 3 times weekly, switch to a formulation that includes alpha-lipoic acid or N-acetylcysteine as copper-chelating co-factors. These compounds bind free copper ions without interfering with peptide-receptor interactions.

Use it only if the chromatogram shows the 4% impurity distributed across baseline noise rather than distinct secondary peaks. A batch with 96% purity and three secondary peaks at 1.5% each contains synthesis byproducts. Truncated sequences, D-amino acid isomers, or acylated fragments. That may interfere with receptor binding or enzyme activity in your experimental model. If the impurity is diffuse background noise, it's likely residual salts or solvents that don't affect biological activity. Request the chromatogram trace and evaluate peak distribution before deciding.

Restart the cycle from day one after a 48-hour washout. FOXO4-DRI senolytic efficacy depends on sustained disruption of the FOXO4–p53 interaction over consecutive days. A single missed dose breaks the apoptotic cascade. Resuming on day two of a broken cycle delivers subtherapeutic exposure that may activate senescent cells without clearing them, potentially increasing inflammatory signalling. The protocol requires uninterrupted daily dosing, which is why pre-planning injection timing around travel, illness, or schedule conflicts is critical before starting.

This is a critical failure. Do not use the product. A mismatch between vial batch number and COA batch number means you have no verified documentation for the specific peptide in your possession. The COA could be legitimate for a different batch, or it could be a fabricated document the supplier uses for all shipments. Contact the supplier and request a corrected COA for your exact batch number. If they cannot provide one, request a refund and source from a different supplier. Our team has encountered this scenario multiple times. It is almost never an administrative error.

Do not use it. Temperature excursions above 25°C cause irreversible structural changes in lyophilized peptides. The damage is cumulative and invisible. Even if the peptide reconstitutes cleanly, you have no way to verify potency without running your own HPLC test. Contact the supplier immediately for a replacement shipped with functional cold-chain packaging. If they refuse or claim 'brief temperature exposure doesn't matter,' find a different vendor. Real Peptides guarantees cold-chain delivery. If your package arrives warm, we reship at no cost because we understand that temperature integrity is non-negotiable for peptide stability.

Discard the vial. Peptide bonds in AOD-9604 denature at temperatures above 8°C. An 8-hour exposure to room temperature (20–22°C) degrades potency by an estimated 50–70% based on accelerated stability testing. There's no visual indicator of partial degradation, and injecting compromised peptide wastes the dose while potentially triggering immune responses to denatured protein fragments.

Administer the missed dose as soon as you remember if fewer than five days have passed since the scheduled injection date, then resume the regular weekly schedule. If more than five days have elapsed, skip the missed dose entirely and continue with the next scheduled administration. Do not double-dose to compensate. Missing doses during the escalation phase may cause temporary return of gastrointestinal symptoms when dosing resumes, as receptor adaptation partially reverses during the gap. Researchers should document missed doses as protocol deviations and assess whether hepatic endpoints are affected in post-hoc analysis.

Request independent third-party verification or source from a supplier who conducts it as standard practice. Manufacturer CoAs verify that the peptide leaving the synthesis facility meets purity specifications. They don't confirm that the peptide arriving at your lab retains structural integrity. A 2021 study in Analytical Chemistry found that 18% of peptides tested from online research suppliers showed molecular weight discrepancies >1 Da compared to theoretical values, indicating synthesis errors or degradation that manufacturer HPLC testing missed. Independent verification eliminates this risk.

Request the full HPLC chromatogram and mass spectrometry report—not just the summary percentage. Identical purity claims (especially round numbers like 98.0% or 99.5%) across different suppliers often indicate recycled or fabricated documentation. Authentic testing produces purity values with decimal precision (e.g., 98.3%, 97.8%) that vary slightly between batches. Additionally, request the testing facility's name and accreditation number—if both suppliers list the same internal lab or provide no facility details, neither result is independently verifiable.

Reduce the dose by 20mcg and consume 20–30g carbohydrates within 90 minutes post-injection. Hypoglycemia during the initial week indicates your baseline insulin sensitivity is higher than average or carbohydrate intake is insufficient. Continue glucose monitoring for 7 days after dose adjustment. Fasting glucose should stabilize between 80–95mg/dL. If symptoms persist at the reduced dose, discontinue and consult a research protocol supervisor.

Increase application frequency to 5 times weekly before increasing dose concentration. Most users who plateau at 3–4 weekly applications see renewed follicle density improvement when moving to 5 applications per week at the same 1mg dose. The mechanism: sustained receptor occupancy matters more than peak concentration. If 5 weekly applications at 1mg still show no improvement by week 12, consider formulation variables. Verify peptide purity via third-party HPLC analysis and confirm vehicle pH is between 5.5–6.5.